(P125) Breast Cancer Outcomes With Anthracycline-Based Chemotherapy for Residual Disease Burden After Full-Dose Neoadjuvant Chemotherapy and Surgery Followed by Radiation Treatment

Publication
Article
OncologyOncology Vol 28 No 1S
Volume 28
Issue 1S

In breast cancer, the primary site residual burden of disease (PRBD) after neoadjuvant chemotherapy has been shown to correlate with poor prognostic outcomes. Currently, there is no established standard of care to offer patients with residual disease, in terms of adjuvant systemic treatment after full-dose neoadjuvant chemotherapy.

Parima Daroui, MD, PhD, Saud Siddiqui, BA, Nilam Ramsinghani, MD, Rita Mehta, MD, Lydia Su, PhD; University of California, Irvine

Introduction: In breast cancer, the primary site residual burden of disease (PRBD) after neoadjuvant chemotherapy has been shown to correlate with poor prognostic outcomes. Currently, there is no established standard of care to offer patients with residual disease, in terms of adjuvant systemic treatment after full-dose neoadjuvant chemotherapy.

Materials and Methods: We retrospectively analyzed data from patients treated on an institutional review board (IRB)-approved institutional protocol of neoadjuvant chemotherapy followed by surgery to determine whether patients with intermediate- or high-grade breast cancer, with T2 disease or greater, and with a PRDB greater than 0.5 cm demonstrate worse outcomes without further adjuvant systemic treatment.

Results: The review included 11 patients with breast cancer treated between 2007–2011 with neoadjuvant chemotherapy followed by mastectomy or lumpectomy and followed by adjuvant radiation treatment (RT). A total of five patients with PRBD greater than 0.5 mm received an additional 3–4 cycles of anthracycline-based chemotherapy after surgery, followed by RT. Six patients with PRBD greater than 0.5 mm had radiation alone after surgery with no additional chemotherapy. Four of the five patients receiving additional systemic treatment for PRBD and all patients treated with RT alone had triple-negative or human epidermal growth factor receptor 2 (HER2)-positive status. On preliminary analysis in a median follow-up of 31 months (range: 18–47 mo) for patients receiving chemotherapy and a median follow-up of 45 months (range: 18–68 mo) for patients receiving RT alone, there was no evidence of disease recurrence (local or distant), based on imaging or clinical examination in any of the 11 patients.

Conclusions: Although limited, these preliminary data may provide a basis for future studies to correlate disease outcomes and pathological data, including initial nodal disease burden and pathological response to treatment.

Articles in this issue

(P113) Age and Marital Status Are Associated With Choice of Mastectomy in Patients Eligible for Breast Conservation Therapy
(P112) Single-Institution Experience With Intrabeam IORT for Treatment of Early-Stage Breast Cancer
(P110) Breast Cancer Before Age 40: Current Patterns in Clinical Presentation and Local Management
(P111) Accelerated Partial-Breast Irradiation With Multicatheter High-Dose-Rate Brachytherapy: Feasibility and Results in a Private Practice Cohort
(P115) Breast Cancer Laterality Does Not Influence Overall Survival in a Large Modern Cohort: Implications for Radiation-Related Cardiac Mortality
(P117) Anatomical Variations and Radiation Technique for Breast Cancer
(P116) Bilateral Immediate DIEP Reconstruction and Postmastectomy Radiotherapy: Experience at a Tertiary Care Institution
(P118) Metadherin Overexpression Is Associated With Improved Locoregional Control After Mastectomy
(P119) Effect of Economic Environment on Use of Postlumpectomy Radiation Therapy for Stage I Breast Cancer
(P120) Immediate Versus Delayed Reconstruction After Mastectomy in the United States Medicare Breast Cancer Patient
(P121) Trend in Age and Racial Disparities in the Receipt of Postlumpectomy Radiation Therapy for Stage I Breast Cancer: 2004–2009
(P122) Streamlining Referring Physicians Orders With ‘Reflex Testing’ Significantly Decreases Time to Resolution for Abnormal Screening Mammograms
(P123) National Trends in the Local Management of Early-Stage Paget Disease of the Breast
(P124) Effect of Inhomogeneity on Cardiac and Lung Dose in Partial-Breast Irradiation Using HDR Brachytherapy
(P125) Breast Cancer Outcomes With Anthracycline-Based Chemotherapy for Residual Disease Burden After Full-Dose Neoadjuvant Chemotherapy and Surgery Followed by Radiation Treatment
Recent Videos
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practice in the breast cancer field.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ASCO Annual Meeting, from hot topics and emerging trends to travel recommendations.
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
Beta emitters like 177Lu-rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer.
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
Clinical trials conducted in recent years demonstrate the benefit of integrative oncology for patients undergoing treatment for cancer.
Related Content